Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA testing. In order to conserve the remaining reagent, a controlled process of batch testing was implemented. Therefore, you will likely see additional delays in receiving these supplemental test results.
Read about our plan to mitigate this on the Communications page by clicking this link: Communications
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...